Pathological significance of abnormal recepteur d’origine nantais and programmed death ligand 1 expression in colorectal cancer

Table 2 Comparison of RON (tumor cells) and PD-L1 (tumor cells) expression and clinicopathological characteristics of patients with colorectal cancer in the FAHZUSM cohort, n (%)

Characteristic	Cases	RON and PD-L1 (TCs) expression in the tumor microenvironment
		RON low/PD-L1 low	RON high/PD-L1 low	RON low/PD-L1 high	RON high/PD-L1 high	P value
Number of cases	290	177	70	18	25
Age (mean ± SD)	60.89 ± 12.215	60.37 ± 12.299	62.40 ± 12.518	58.39 ± 12.930	62.12 ± 10.179	0.495
Sex
Man	161 (55.5)	108 (61)	35 (50.0)	9 (50.0)	9 (36.0)	0.061
Women	129 (44.5)	68 (39)	35 (50.0)	9 (50.0)	16 (64.0)
Principal diagnosis				s
Rectum	182 (62.8)	116 (65.5)	37 (52.9)	14 (77.8)	15 (60.0)	0.149
Colon	108 (37.2)	61 (34.5)	33 (47.1)	4 (22.2)	10 (40.0)
Pathological grade
Well/moderate	6 (2.1)	3 (1.7)	2 (2.9)	0 (0.0)	1 (4.0)	0.264
Poor	264 (9.1)	158 (89.3)	66 (94.3)	16 (88.9)	24 (96.0)
Unknown	20 (6.9)	16 (9.0)	2 (2.9)	2 (11.1)	0 (0.0)
T stage
Tis-T2	84 (29)	64 (36.2)	9 (12.9)	5 (27.8)	6 (24.0)	0.003
T3	140 (48.3)	82 (46.3)	36 (51.4)	11 (61.1)	11 (44.0)
T4	66 (22.8)	31 (17.5)	25 (35.7)	2 (11.1)	8 (32.0)
N stage
N0	238 (66.9)	125 (70.6)	39 (55.7)	12 (66.7)	13 (66.4)	0.072
N (1-2)	118 (33.1)	52 (29.4)	31 (44.3)	6 (33.3)	12 (33.6)
M stage
M0	283 (97.6)	173 (97.7)	68 (97.1)	18 (100)	24 (96.0)	0.735
M1	7 (2.4)	4 (2.3)	2 (2.9)	0 (0.0)	1 (4.0)
Stage
0-II	187 (64.5)	123 (69.5)	39 (55.7)	12 (66.7)	13 (52.0)	0.110
III-IV	103 (35.5)	54 (30.5)	31 (33.3)	6 (33.3)	12 (48.0)
Histological type
Adenocarcinoma	251 (86.6)	152 (85.9)	62 (88.6)	15 (83.3)	22 (88.0)	0.493
Mucinous/SRCC	32 (11)	21 (11.9)	7 (10.0)	1 (5.6)	3 (12.0)
Other	7 (2.4)	4 (2.3)	1 (1.4)	2 (11.1)	0 (0.0)
Treatment
Yes	135 (46.6)	83 (46.9)	22 (31.4)	6 (33.3)	12 (48.0)	0.158
No	119 (41.0)	74 (41.8)	38 (54.3)	11 (61.1)	8 (32.0)
Unknown	36 (12.4)	20 (11.3)	10 (14.3)	1 (5.6)	5 (20.0)

Bold entries indicate statistical significance (P < 0.05). RON: Recepteur d’origine nantais; PD-L1: Programmed death ligand 1; TCs: Tumor cells; FAHZUSM: The First Affiliated Hospital, Zhejiang University School of Medicine.